Q2 2025: 10 FDA Decisions to Watch

The first quarter of 2025 set a high bar for drug approvals, with the US Food and Drug Administration (FDA) greenlighting several groundbreaking therapies. Suzetrigine (Journavx), a nonopioid pain reliever, broke a decades-long drought in FDA approvals for this critical area of unmet need. Meanwhile, semaglutide (Ozempic) expanded its reach, earning an indication for chronic kidney disease in type 2 diabetes, and esketamine (Spravato) made history as the first monotherapy for treatment-resistant depression.